论文部分内容阅读
通过软坚护肝片对能产生全部乙肝病毒指标细胞株的抑制试验和临床初步应用的结果，说明该药有抑制乙肝病毒ＨＢｅＡｇ，ＨＢｓＡｇ的作用，治疗指数（ＴＩ）分别为＞５．７４及＞１０．２１（ＴＩ＞２为有效）。临床应用的ＨＢｓＡｇ转阴率为２８％—５７％，ＨＢｅＡｇ转阴率达７８％，动物实验结果表明：软坚护肝片有减轻ＣＣｌ４及硫代乙酰胺所致小鼠急性肝损伤的作用，有减轻Ｄ—氨基半乳糖所致大鼠急性肝损伤的作用，其降低小鼠血清ＡＬＴ活性的作用，并非通过直接抑制ＡＬＴ而产生，对正常小鼠的血清ＡＬＴ活动无明显影响。此外，尚有提高小鼠碳粒廓清能力及血清溶血素生成的作用。
The results showed that the drug has the effect of inhibiting the HBeAg and HBsAg of hepatitis B virus and the treatment index (TI) is> 5.74 and> 10.21 (TI> 2 is valid). The clinical application of HBsAg negative rate of 28% -57%, HBeAg negative rate of 78%, animal experiments showed that: soft Jiangangan tablet can reduce CCl4 and thioacetamide-induced acute liver injury in mice, there are The effect of reducing the acute hepatic injury induced by D-galactosamine in mice is not caused by the direct inhibition of ALT but has no significant effect on the serum ALT activity in normal mice. In addition, there is still to improve the ability of mice carbon clearance and serum hemolysin production role.